No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin

<p>Abstract</p> <p>Background</p> <p>The mechanisms of chemoresistance in ovarian cancer patients remain largely to be elucidated. Paclitaxel/cisplatin combination is the standard chemotherapeutic treatment for this disease, although some patients do not respond to ther...

Full description

Bibliographic Details
Main Authors: Pinto Carla, Pinto Isabel M, Tavares Ana, Pereira Deolinda, Veiga Isabel, Mesquita Bárbara, Teixeira Manuel R, Castedo Sérgio
Format: Article
Language:English
Published: BMC 2005-08-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/5/101

Internet

http://www.biomedcentral.com/1471-2407/5/101

Similar Items